Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Sep 21;355(12):1199-209.
doi: 10.1056/NEJMoa055706.
Svein Solheim, Svend Aakhus, Harald Arnesen, Michael Abdelnoor, Torstein Egeland, Knut Endresen, Arnfinn Ilebekk, Arild Mangschau, Jan G Fjeld, Hans Jørgen Smith, Eli Taraldsrud, Haakon Kiil Grøgaard, Reidar Bjørnerheim, Magne Brekke, Carl Müller, Einar Hopp, Asgrimur Ragnarsson, Jan E Brinchmann, Kolbjørn Forfang
Affiliations
- PMID: 16990383
- DOI: 10.1056/NEJMoa055706
Free article
Randomized Controlled Trial
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction
Ketil Lunde et al. N Engl J Med. 2006.
Free article
Abstract
Background: Previous studies have shown improvement in left ventricular function after intracoronary injection of autologous cells derived from bone marrow (BMC) in the acute phase of myocardial infarction. We designed a randomized, controlled trial to further investigate the effects of this treatment.
Methods: Patients with acute ST-elevation myocardial infarction of the anterior wall treated with percutaneous coronary intervention were randomly assigned to the group that underwent intracoronary injection of autologous mononuclear BMC or to the control group, in which neither aspiration nor sham injection was performed. Left ventricular function was assessed with the use of electrocardiogram-gated single-photon-emission computed tomography (SPECT) and echocardiography at baseline and magnetic resonance imaging (MRI) 2 to 3 weeks after the infarction. These procedures were repeated 6 months after the infarction. End points were changes in the left ventricular ejection fraction (LVEF), end-diastolic volume, and infarct size.
Results: Of the 50 patients assigned to treatment with mononuclear BMC, 47 underwent intracoronary injection of the cells at a median of 6 days after myocardial infarction. There were 50 patients in the control group. The mean (+/-SD) change in LVEF, measured with the use of SPECT, between baseline and 6 months after infarction for all patients was 7.6+/-10.4 percentage points. The effect of BMC treatment on the change in LVEF was an increase of 0.6 percentage point (95% confidence interval [CI], -3.4 to 4.6; P=0.77) on SPECT, an increase of 0.6 percentage point (95% CI, -2.6 to 3.8; P=0.70) on echocardiography, and a decrease of 3.0 percentage points (95% CI, 0.1 to -6.1; P=0.054) on MRI. The two groups did not differ significantly in changes in left ventricular end-diastolic volume or infarct size and had similar rates of adverse events.
Conclusions: With the methods used, we found no effects of intracoronary injection of autologous mononuclear BMC on global left ventricular function.
Trial registration: ClinicalTrials.gov NCT00199823.
2006 Massachusetts Medical Society
Comment in
- The politics and promise of stem-cell research.
Schwartz RS. Schwartz RS. N Engl J Med. 2006 Sep 21;355(12):1189-91. doi: 10.1056/NEJMp068180. N Engl J Med. 2006. PMID: 16990380 No abstract available. - Cardiac cell therapy--mixed results from mixed cells.
Rosenzweig A. Rosenzweig A. N Engl J Med. 2006 Sep 21;355(12):1274-7. doi: 10.1056/NEJMe068172. N Engl J Med. 2006. PMID: 16990391 No abstract available.
Similar articles
- Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function.
Yao K, Huang R, Qian J, Cui J, Ge L, Li Y, Zhang F, Shi H, Huang D, Zhang S, Sun A, Zou Y, Ge J. Yao K, et al. Heart. 2008 Sep;94(9):1147-53. doi: 10.1136/hrt.2007.137919. Epub 2008 Apr 1. Heart. 2008. PMID: 18381377 Clinical Trial. - Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
Dill T, Schächinger V, Rolf A, Möllmann S, Thiele H, Tillmanns H, Assmus B, Dimmeler S, Zeiher AM, Hamm C. Dill T, et al. Am Heart J. 2009 Mar;157(3):541-7. doi: 10.1016/j.ahj.2008.11.011. Epub 2009 Jan 31. Am Heart J. 2009. PMID: 19249426 Clinical Trial. - Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.
Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Meyer GP, et al. Circulation. 2006 Mar 14;113(10):1287-94. doi: 10.1161/CIRCULATIONAHA.105.575118. Epub 2006 Mar 6. Circulation. 2006. PMID: 16520413 Clinical Trial. - Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials.
Delewi R, Andriessen A, Tijssen JG, Zijlstra F, Piek JJ, Hirsch A. Delewi R, et al. Heart. 2013 Feb;99(4):225-32. doi: 10.1136/heartjnl-2012-302230. Epub 2012 Aug 8. Heart. 2013. PMID: 22875736 Review.
Cited by
- Generation of Directly Reprogrammed Human Endothelial Cells.
Cho S, Xia I, Lee S, Park C, Yoon YS. Cho S, et al. Methods Mol Biol. 2024;2835:155-164. doi: 10.1007/978-1-0716-3995-5_14. Methods Mol Biol. 2024. PMID: 39105914 - Revascularization of chronic total occlusion coronary artery and cardiac regeneration.
Liao R, Li Z, Wang Q, Lin H, Sun H. Liao R, et al. Front Cardiovasc Med. 2022 Aug 25;9:940808. doi: 10.3389/fcvm.2022.940808. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36093131 Free PMC article. Review. - Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells.
Poole JC, Quyyumi AA. Poole JC, et al. Stem Cells Int. 2013;2013:658480. doi: 10.1155/2013/658480. Epub 2013 Apr 28. Stem Cells Int. 2013. PMID: 23737803 Free PMC article. - Clinical efficacy and safety of autologous stem cell transplantation for patients with ST-segment elevation myocardial infarction.
Li R, Li XM, Chen JR. Li R, et al. Ther Clin Risk Manag. 2016 Aug 1;12:1171-89. doi: 10.2147/TCRM.S107199. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27536122 Free PMC article. - Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells.
Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marbán L, Marbán E. Li TS, et al. J Am Coll Cardiol. 2012 Mar 6;59(10):942-53. doi: 10.1016/j.jacc.2011.11.029. J Am Coll Cardiol. 2012. PMID: 22381431 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical